Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lopinavir

FDA-approved product (capsule, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lopinavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Lopinavir reaches ≥40% AI-predicted activity against M. tuberculosis and MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lopinavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lopinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

    NCT04487145 · start 2020-11-23

    Registered record
    Registry ID
    NCT04487145
    Conditions
    Drug-Drug Interaction; HIV Infection
    Interventions
    Dihydroartemisinin-piperaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-11-23
    Completion
    2022-04-11
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Drug Interaction; HIV Infection
    InterventionDihydroartemisinin-piperaquine
    PhasePhase 4
    Registry statusCompleted

  • Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

    NCT04386447 · start 2020-09-01

    Registered record
    Registry ID
    NCT04386447
    Conditions
    Covid-19; Corona Virus Infection; SARS-CoV 2
    Interventions
    Oxytocin; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-09-01
    Completion
    2020-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19; Corona Virus Infection; SARS-CoV 2
    InterventionOxytocin; Standard of Care
    PhasePhase 2
    Registry statusWithdrawn

  • Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

    NCT04542694 · start 2020-05-21

    Registered record
    Registry ID
    NCT04542694
    Conditions
    COVID-19
    Interventions
    Favipiravir; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-05-21
    Completion
    2020-08-20
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionFavipiravir; Standard of care
    PhasePhase 3
    Registry statusCompleted

  • An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

    NCT04343768 · start 2020-04-09

    Registered record
    Registry ID
    NCT04343768
    Conditions
    COVID-19
    Interventions
    Hydroxychloroquine; Lopinavir / Ritonavir; Interferon Beta-1A; Interferon Beta-1B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-04-09
    Completion
    2020-04-27
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionHydroxychloroquine; Lopinavir / Ritonavir; Interferon Beta-1A; Interferon Beta-1B
    PhasePhase 2
    Registry statusCompleted

  • Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive

    NCT04333589 · start 2020-04-01

    Registered record
    Registry ID
    NCT04333589
    Conditions
    COVID-19
    Interventions
    Favipiravir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-04-01
    Completion
    2020-09-15
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionFavipiravir
    PhaseNot applicable
    Registry statusUnknown

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

    NCT04261907 · start 2020-02-11

    Registered record
    Registry ID
    NCT04261907
    Conditions
    2019-nCoV
    Interventions
    ASC09/ritonavir group; lopinavir/ritonavir group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-02-11
    Completion
    2020-04-13
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2019-nCoV
    InterventionASC09/ritonavir group; lopinavir/ritonavir group
    PhaseNot applicable
    Registry statusTerminated

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

    NCT02581202 · start 2015-12-21

    Registered record
    Registry ID
    NCT02581202
    Conditions
    HIV-1 Infection
    Interventions
    lopinavir/ritonavir; lamivudine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-12-21
    Completion
    2017-05-27
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionlopinavir/ritonavir; lamivudine
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children

    NCT01818258 · start 2015-10-26

    Registered record
    Registry ID
    NCT01818258
    Conditions
    HIV Positive; Malnourished
    Interventions
    ZDV+3TC+LPV/r
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-10-26
    Completion
    2017-09-29
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Positive; Malnourished
    InterventionZDV+3TC+LPV/r
    PhasePhase 4
    Registry statusCompleted

  • Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)

    NCT02346487 · start 2015-09

    Registered record
    Registry ID
    NCT02346487
    Conditions
    HIV
    Interventions
    LPV/RTV pellets and AZT/3TC or ABC/3TC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2019-05-14
    Enrolment
    1,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionLPV/RTV pellets and AZT/3TC or ABC/3TC
    PhasePhase 3
    Registry statusCompleted

  • HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

    NCT02513147 · start 2015-06

    Registered record
    Registry ID
    NCT02513147
    Conditions
    HIV-1
    Interventions
    Dolutegravir; PI; 2 NRTI; 2 NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDolutegravir; PI; 2 NRTI; 2 NRTI
    PhasePhase 4
    Registry statusCompleted

  • Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

    NCT02140255 · start 2015-01-23

    Registered record
    Registry ID
    NCT02140255
    Conditions
    HIV Infection
    Interventions
    Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP); Lopinavir/Ritonavir (LPV/r); Raltegravir (RAL); VRC01; Dolutegravir (DTG); VRC07-523LS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2015-01-23
    Completion
    2031-12-31
    Enrolment
    1,120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP); Lopinavir/Ritonavir (LPV/r); Raltegravir (RAL) +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted